Beirut, LEBANON; Cliintel, Centennial, CO; Covalense Technologies Ltd., Hyderabad, INDIA; Cricket Wireless, San Diego, CA; CTC Ltd., Kyiv, UKRAINE; Enhancesys Innovations
LLC, Cupertino, CA; EPAEON LTD, Nicosia, CYPRUS; E-Plus Mobilfunk GmbH \& Co. KG, Duesseldorf, GERMANY; Intel Corporation, Santa Clara, CA; Iskratel, d.o.o., Kranj, SLOVENIA; Laboratory For TelecommFaculty of Elect. Eng. University of Ljubljana, Ljubljana, SLOVENIA; Limtel Sp. z o.o., Olsztyn, POLAND; Mendix Inc., Boston, MA; Mirus Teknologia, Osterville, MA; Modern Times Group MTG AB, Stockholm, SWEDEN; Network Rail, Milton Keynes, UNITED KINGDOM; NetYCE, Amsterdam, THE NETHERLANDS; New South Wales Government Telecommunications Authority, Sydney, AUSTRALIA; NII Holdings, Inc., Reston, VA; Nordiska Servercentralen AB, Bromma, SWEDEN; Olds Fibre Ltd., Olds, CANADA; Omera Consulting P/S, Copenhagen,
DENMARK; Pacific Broadband Networks Limited, Scoresby, AUSTRALIA; Petrobras, Rio de Janeiro, BRAZIL; Proxwel, Bizerte, TUNISIA; Resolvetel Ltd., Henley-on-Thames, UNITED KINGDOM; Selex ES, Rome, ITALY; Singer TC GmbH, Schwedeneck, GERMANY; SLA Mobile, Belfast, UNITED KINGDOM; Smart Information Systems Gmbh, Vienna, AUSTRIA; Systex Corporation, Taipei, TAIWAN; TELEMAR NORTE LESTE S.A., Rio de Janeiro, BRAZIL; TOA Technologies, Inc., Beachwood, OH; University of Stuttgart, Stuttgart, GERMANY;
Univision LLC, Ulaanbaatar,
MONGOLIA; VDVL, Rijswijk, THE NETHERLANDS; Viasat, Inc., Carlsbad, CA; VIP Operator, Skopje,
MACEDONIA; Vodacom (Pty) Ltd.,
Midrand, SOUTH AFRICA; WebRadar,
Rio de Janeiro, BRAZIL; wwite p/l,
Eaglemont, AUSTRALIA; Zain Kuwait, Kuwait City, KUWAIT; Zettics, Seattle, WA; beCloud, Minsk, BELARUS; CORRELOR TECHNOLOGIES PTE. LTD., Singapore, SINGAPORE; Innovise ESM Ltd., Slough, UNITED KINGDOM; Kwezi Software Solutions, Woodmead, SOUTH AFRICA; Maksen Consulting, S.A., Lisbon, PORTUGAL; Maxis Broadband Sdn Bhd, Kuala Lumpur, MALAYSIA; Mediaan/abs bv, Heerlen, THE NETHERLANDS; Polish Telephones Foundation, Warszawa, POLAND; Portugal Telecom Inovacao, SA, Aveiro, PORTUGAL; PT Comunicacoes, Lisbon, PORTUGAL; SAPO (PT Comunicacoes), Lisbon, PORTUGAL; Softera Oy, Helsinki, FINLAND; Telecom Argentina, S.A., Buenos Aires, ARGENTINA; Telefonica

Global Technology SA, Caba, ARGENTINA; Ufone, Islamabad, PAKISTAN; Vodafone India Limited, Mumbai, INDIA; and Zain KSA, Riyadh, SAUDI ARABIA.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and The Forum intends to file additional written notifications disclosing all changes in membership.

On October 21, 1988, The Forum filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on December 8, 1988 (53 FR 49615).

The last notification was filed with the Department on April 21, 2015. A notice was published in the Federal Register pursuant to section 6(b) of the Act on May 27, 2015 ( 80 FR 30268).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2015-18627 Filed 7-29-15; 8:45 am] BILLING CODE P

## DEPARTMENT OF JUSTICE

## Drug Enforcement Administration [Docket No. DEA-392]

## Manufacturer of Controlled Substances Registration: Apertus Pharmaceuticals

ACTION: Notice of registration.
summary: Apertus Pharmaceuticals applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Apertus Pharmaceuticals registration as a manufacturer of those controlled substances.
SUPPLEMENTARY INFORMATION: By notice dated March 20, 2015, and published in the Federal Register on March 27, 2015, 80 FR 16440, Apertus Pharmaceuticals, 331 Consort Drive, St. Louis, Missouri 63011 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted to this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Apertus
Pharmaceuticals to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed:

| Controlled substance | Schedule |
| :---: | :--- |
| Marihuana (7360) ........................ | I |
| Tetrahydrocannabinols (7370) $\ldots .$. | I |

The company plans to divide the synthesized cannabidiol, with a portion going for sale as an API in nabiximol. The raw material will be used to synthesize dronabinol. Therefore, they anticipate consuming and purchasing small quantities of CS for generating data to support the Drug Master File with the FDA including validation batches, standards and stability studies.

No other activity for this drug code is authorized for this registration.

Dated: July 23, 2015.

## Joseph T. Rannazzisi,

Deputy Assistant Administrator.
[FR Doc. 2015-18695 Filed 7-29-15; 8:45 am] BILLING CODE P

## DEPARTMENT OF JUSTICE

Drug Enforcement Administration
[Docket No. DEA-392]

## Manufacturer of Controlled Substances Registration: Cambridge Isotope Lab

ACTION: Notice of registration.
summary: Cambridge Isotope Lab applied to be registered as a manufacturer of a certain basic class of controlled substance. The Drug Enforcement Administration (DEA) grants Cambridge Isotope Lab registration as a manufacturer of this controlled substance.
sUPPLEMENTARY INFORMATION: By notice dated February 5, 2015, and published in the Federal Register on February 11, 2015, 80 FR 7635, Cambridge Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810 applied to be registered as a manufacturer of a certain basic class of controlled substance. No comments or objections were submitted to this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambridge Isotope Lab to manufacture the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of morphine (9300), a basic class of controlled substance listed in schedule II.
The company plans to utilize small quantities of the listed controlled substance in the preparation of analytical standards.
Dated: July 23, 2015.

## Joseph T. Rannazzisi,

Deputy Assistant Administrator.
[FR Doc. 2015-18693 Filed 7-29-15; 8:45 am]
BILLING CODE 4410-09P

## DEPARTMENT OF JUSTICE

## Drug Enforcement Administration

[Docket No. DEA-392]
Importer of Controlled Substances Registration: Stepan Company

ACTION: Notice of registration.
SUMMARY: Stepan Company applied to be registered as an importer of certain basic class of controlled substances. The Drug Enforcement Administration (DEA) grants Stepan Company registration as an importer of this controlled substance.
SUPPLEMENTARY INFORMATION: By notice dated April 14, 2015, and published in
the Federal Register on April 22, 2015, 80 FR 22561, Stepan Company, Natural Products Dept., 100 W. Hunter Avenue, Maywood, New Jersey 07607 applied to be registered as an importer of a certain basic class of controlled substance. Comments and request for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417 (January 25, 2007).

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of Stepan Company to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above-named company is granted registration as an importer of coca leaves (9040) a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance to manufacture bulk controlled substances for distribution to its customers.

Dated: July 23, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-18691 Filed 7-29-15; 8:45 am]
BILLING CODE $P$


